ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the present study, supported by In Silico analyses, we have shown for the first time the direct antagonistic effect of Notch/Hes-1 and BCR-ABL, and we have shown that inhibition of Notch signalling directly suppresses the overexpression of Hes-1 in CML primary cells, which provides a rationale for the development of combinational therapeutic strategies targeting Notch and BCR-ABL in chronic phase CML.